Gleevec's Latest Approval is for Pediatric Cancer
Other news for:|
| ||Resources from
Drug blocks proteins that fuel cancer-cell development
By Scott Roberts
FRIDAY, Jan. 25 (HealthDay News) -- The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said Friday.
Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) progresses rapidly if left untreated. Gleevec, among a class of drugs called tyrosine kinase inhibitors, blocks proteins that promote development of cancer cells, the FDA said in a news release.
The most common side effects observed in pediatric testing included infection and a decrease in white blood cells and blood platelets.
Gleevec was first approved in 2001 to treat a form of chronic myeloid leukemia, and has since been approved to treat several other conditions. The drug is marketed by Novartis, based in East Hanover, N.J.
To learn more about Gleevec, visit the U.S. .
Copyright © 2013 . All rights reserved.
Resources from HONselect:
HONselect is the HON's medical search engine.
It retrieves scientific articles, images, conferences and web sites on the
The list of medical terms above are retrieved automatically from the article.
The text presented on this page is not a substitute for professional
medical advice. It is for your information only and may not represent your true
individual medical situation. Do not hesitate to consult your healthcare provider
if you have any questions or concerns. Do not use this information to diagnose or
treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources
and may not reflect your own country regulations.
The Health On the Net Foundation does not endorse opinions,
products, or services that may appear in HealthDay articles.